Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application
Rhizen today announced the approval of IND application by the U.S. FDA to study its oral DHODH inhibitor for SARS-CoV-2 infection.

Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.


Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct-acting antiviral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine-mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.

Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19”.

Tags : #LatestPharmaNewsDec4 #LatestRhizenNewsDec4 #TreatmentforCovid

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Murder in the Name of God: Kashmir and the Collapse of HumanityApril 24, 2025
6 Early Warning Signs of Malaria You Shouldn’t IgnoreApril 24, 2025
World Meningitis Day: A Loud Alarm for a Quiet KillerApril 24, 2025
Amid Documented Progress, India’s Malaria-Free Dream Faces Ground Realities.April 24, 2025
Medanta Surgeons Remove Rare Tumour, Rebuild Face of Iraqi Toddler in 14-Hour Surgery.April 24, 2025
Burnett Homeopathy Hosts Historic World Homeopathy Summit 3 During World Homeopathy Week in Germany April 24, 2025
Mind Over Meltdown: The Underrated Skill Saving Relationships and SanityApril 23, 2025
Moscow Accelerates AI Testing in Healthcare with New Diagnostic MethodApril 23, 2025
The Weight Loss Drug That Could Weigh Down Your Mind: A Closer Look at Ozempic’s Hidden CostApril 23, 2025
The Chaos That Makes You Human: How Disorder in the Brain Creates Order in ThoughtApril 23, 2025
Benefiting 7,000 Children Across 30 Schools with CSR InitiativesApril 23, 2025
MGM Healthcare Performs Life-Saving Surgery on 6-Year-Old Boy with Severe Heart BlockageApril 23, 2025
5 Ways Rheumatic Diseases Affect Women DifferentlyApril 23, 2025
Centrum launches Centrum Recharge Energy Drink Mix with Brand Ambassador Anushka SharmaApril 23, 2025
Hair Fall Is No Longer a Headache – A New Non-Surgical Super Treatment Is Here”April 23, 2025
Herbalife India Launches Sleep EnhanceTM April 23, 2025
Sharda Care Healthcity Successfully Removes Massive 16.5 kg Ovarian Tumour in High-Risk PatientApril 23, 2025
Lighthouse Canton White Paper Projects 3,200 Single-Family Offices in Asia Pacific by 2030 April 22, 2025
CSK Players Meet “Let’s READ” beneficiaries with FedEx CaresApril 22, 2025
Atherosclerosis: The Hidden Threat to Your HeartApril 22, 2025